[HTML][HTML] Heart disease and stroke statistics-2021 update: a report from the American Heart Association.
Background The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …
Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial
SB Heitner, D Jacoby, SJ Lester, A Owens… - Annals of internal …, 2019 - acpjournals.org
Background: Mavacamten, an orally administered, small-molecule modulator of cardiac
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …
myosin, targets underlying biomechanical abnormalities in obstructive hypertrophic …
Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry
S Neubauer, P Kolm, CY Ho, RY Kwong… - Journal of the American …, 2019 - jacc.org
Abstract Background: The HCMR (Hypertrophic Cardiomyopathy Registry) is a National
Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with …
Heart, Lung, and Blood Institute–funded, prospective registry of 2,755 patients with …
Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy
SM Hegde, SJ Lester, SD Solomon, M Michels… - Journal of the American …, 2021 - jacc.org
Abstract Background EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461]
in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that …
in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) demonstrated that …
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial
Hypertrophic cardiomyopathy (HCM) is often caused by pathogenic variants in sarcomeric
genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and …
genes and characterized by left ventricular (LV) hypertrophy, myocardial fibrosis and …
A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy
Background: Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk …
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk …
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies
Hypertrophic cardiomyopathy (HCM) was traditionally described as an autosomal dominant
Mendelian disease but is now increasingly recognized as having a complex genetic …
Mendelian disease but is now increasingly recognized as having a complex genetic …
Vigorous exercise in patients with hypertrophic cardiomyopathy
R Lampert, MJ Ackerman, BS Marino, M Burg… - JAMA …, 2023 - jamanetwork.com
Importance Whether vigorous intensity exercise is associated with an increase in risk of
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown …
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown …
Hypertrophic cardiomyopathy: the future of treatment
CV Tuohy, S Kaul, HK Song, B Nazer… - European journal of …, 2020 - Wiley Online Library
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility …
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility …
Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe registry
Background: The term “end stage” has been used to describe hypertrophic cardiomyopathy
(HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left …
(HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left …